Germantown’s Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock

Published on : January 22, 2021January 22, 2021 Published by : BioBuzz Media

$7.50 per share

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

Published on : January 11, 2021January 12, 2021 Published by : BioBuzz Media

Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.

Annual BioHealth Capital Region Forum Showcases Robust Growth Across 4th Largest Biopharma Cluster

Published on : October 20, 2020October 20, 2020 Published by : Alex Keown

The Sixth Annual BioHealth Capital Region Forum brought together industry leaders from across the region who discussed the accomplishments and strengths of the region as its member companies continue to innovate new therapies and medicines in one of the strongest bio-hub regions in the United States.

Experts Weigh in on the Role of Lab Automation and Sensor Technology in Advancing the Cell Therapy and Regenerative Medicine Fields

Published on : October 6, 2020November 5, 2020 Published by : Steven Surdez

While there is tremendous excitement and ample investment around cell and gene therapy and regenerative medicine, several challenges, including scale-up, high manufacturing costs, and regulatory hurdles, continue to be impediments to the industry achieving its potential.

5 Questions with Mike O’Mara, VP of Industrial Business Services, Miltenyi Biotec

Published on : September 29, 2020November 3, 2020 Published by : Andy Eckert

Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.

MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer

Published on : September 17, 2020September 17, 2020 Published by : Chris Frew

Amanda L. Murphy Appointed as Chief Financial Officer to MaxCyte

Kite Seeking to Hire Cell Therapy Talent Ahead of Opening Its New Advanced Biomanufacturing Facility in Frederick, Maryland

Kite Cell Therapy Specialist Jobs Frederick, MD

Published on : August 7, 2020December 9, 2020 Published by : Steven Surdez

A year and a half after announcing their plans to build a state-of-the-art cell manufacturing facility in Frederick County, Maryland, Kite, a Gilead Company, is looking to fill dozens of new biomanufacturing jobs in Maryland and add to the talented site team it already has in place.

5 Questions with Jeff Galvin, CEO and Founder of American Gene Technologies™

Published on : August 4, 2020September 28, 2020 Published by : Andy Eckert

Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups.

Why Advanced Biomanufacturing in Maryland is a Thriving Industry

Published on : July 29, 2020August 24, 2020 Published by : Chris Frew

Why Advanced Biomanufacturing in Maryland is a Thriving Industry These Four Industry-leading BioManufacturing Companies Represent Thousands of Jobs in Maryland and Are Shaping the Future of Medicine A burgeoning cell [….]

BroadOak Capital Partners Appoints Bryan Poltilove as Managing Director

Published on : July 6, 2020July 8, 2020 Published by : Chris Frew

Bryan Poltilove is a Managing Director focused on guiding BroadOak’s growth capital investing strategy and advising portfolio companies in the life sciences and cell and gene therapy sectors.